Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is expected to achieve a net profit attributable to shareholders of 63 million yuan in 2025, representing a year-on-year increase of 46%. The growth is supported by the expansion into overseas markets and new application fields [5][8] - The company's revenue for 2025 is projected to be 406 million yuan, reflecting a year-on-year growth of 19.62%. This growth is driven by the synergy of three major business segments: vaccine culture media, food nutrition products, and raw materials [8] - The company is actively establishing overseas subsidiaries to enhance market presence and streamline trade processes, which is expected to contribute to long-term growth [8] Financial Summary - Revenue Forecast: - 2023: 389 million yuan - 2024: 339 million yuan (decrease of 12.87%) - 2025E: 406 million yuan (increase of 19.62%) - 2026E: 482 million yuan (increase of 18.98%) - 2027E: 573 million yuan (increase of 18.73%) [7] - Net Profit Forecast: - 2023: 53 million yuan - 2024: 43 million yuan (decrease of 19.76%) - 2025E: 63 million yuan (increase of 46.38%) - 2026E: 79 million yuan (increase of 25.87%) - 2027E: 97 million yuan (increase of 23.12%) [7] - Earnings Per Share (EPS): - 2023: 0.69 yuan - 2024: 0.55 yuan - 2025E: 0.81 yuan - 2026E: 1.02 yuan - 2027E: 1.25 yuan [7] - Price-to-Earnings Ratio (P/E): - 2025E: 29.29 - 2026E: 23.27 - 2027E: 18.90 [7]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company is expected to see a 46.39% year-on-year increase in net profit attributable to shareholders, with projected revenue of 406 million yuan for 2025 [4] - The core business segments are experiencing a recovery in demand, contributing to stable revenue and profit growth [4] - The company is actively expanding into new product categories and enhancing its overseas business presence [5] Financial Summary - Total revenue is projected to grow from 389 million yuan in 2023 to 662 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 23.7% [7] - Net profit attributable to shareholders is expected to increase from 53 million yuan in 2023 to 103 million yuan in 2027, with a significant growth rate of 18.4% in 2027 [7] - The company's gross margin is projected to stabilize around 30.6% from 2026 onwards [8] Business Development - The company has established a presence in overseas markets, with external sales accounting for approximately 56.88% of total revenue as of Q3 2025 [5] - New factories are in trial production, which will help address capacity constraints once regulatory approvals are obtained [5] - The company plans to diversify its product offerings beyond amino acids to include derivatives, functional peptides, and other innovative products [4]